Site Editor
Al B. Benson III, MD, FACP, FASCO
Al B. Benson III, MD, FACP, FASCO
Posted: Friday, October 14, 2022
According to research presented in the Annals of Surgical Oncology, identifying the systemic immune inflammation index (SII) score of some patients with extrahepatic cholangiocarcinoma who undergo resection may help identify appropriate options for adjuvant therapy. In this patient population, the SII score was observed to be independently associated with postoperative survival outcomes.
“SII may be a simple, cost-effective, and [easy-to-use] means to better stratify patients relative to prognosis following resection of [extrahepatic cholangiocarcinoma], as well as help to identify those individuals most likely to benefit from [adjuvant therapy],” concluded Timothy M. Pawlik, MD, PhD, of The Ohio State University Wexner Medical Center, Columbus, and colleagues.
The study included 485 patients who underwent curative resection between 1998 and 2017. A total of 231 patients (47.6%) were identified as having a low SII score, whereas 254 patients (52.4%) had a high SII score. The SII score is based on neutrophil, platelet, and lymphocyte counts, with a lower score being ≤ 403 and a higher score being > 403.
Multivariate analysis revealed an association between high SII scores and worse survival outcomes; patients with high SII scores had poorer 5-year overall survival (15.9% vs. 27.9%) and relapse-free survival (12.4% vs. 20.9%) than those with low SII scores. Relative to correlation with survival outcomes, SII scores upstaged patients’ tumor (T) and node (N) scores. Worse 5-year overall survival outcomes were observed in patients with T1 or T2 disease and high SII scores versus those with T3 or T4 disease and low SII scores (16.4% vs. 35.6%), whereas comparable 5-year overall survival outcomes were reported in patients with N0 and high SII scores versus those with N1 and low SII scores (23.2% vs. 19.8%). Propensity score matching indicated that overall survival and relapse-free survival were improved after adjuvant therapy for patients with high SII scores but not for those with low SII scores.
Disclosure: The study authors reported no conflicts of interest.
